Core Viewpoint - Alvotech has filed its Annual Report 2025 with the U.S. Securities and Exchange Commission, highlighting its commitment to transparency and regulatory compliance [1]. Company Overview - Alvotech is a biotechnology company focused on developing and manufacturing biosimilar medicines globally [2]. - The company aims to be a leader in the biosimilars market by providing high-quality, cost-effective products through a fully integrated approach and extensive in-house capabilities [2]. - Alvotech has five biosimilars approved and marketed in various global markets, including those for Humira®, Stelara®, Simponi®, Eylea®, and Prolia®/Xgeva® [2]. - The current development pipeline includes nine disclosed biosimilar candidates targeting autoimmune disorders, eye disorders, osteoporosis, respiratory diseases, and cancer [2]. - Alvotech has established strategic commercial partnerships to enhance its global reach and leverage local expertise across markets such as the United States, Europe, Japan, China, and parts of South America, Africa, and the Middle East [2].